Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced disappointing results from its Phase 3 studies for setrusumab (UX143). Add in a flurry of analysts slashing their price targets on Ultragenyx stock, and it's clear why investors are clicking the sell button today.
As of 2:45 p.m. ET, shares of Ultragenyx are down 43.5%.
Image source: Getty Images.
Source Fool.com
Ultragenyx Pharmaceutical Inc. Stock
?
0.510%
With 25 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 57 € there is potential for a 187.88% increase which would mean more than doubling the current price of 19.8 € for Ultragenyx Pharmaceutical Inc..
